VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q40728421 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010710.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q40728421‏
024 ‎‡a 0000-0002-1245-3715‏ ‎‡2 orcid‏
024 ‎‡a 57200002849‏ ‎‡2 scopus‏
024 ‎‡a 57200289025‏ ‎‡2 scopus‏
024 ‎‡a 7103326175‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q40728421‏
100 0 ‎‡a Joao Goncalves‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Joao Goncalves‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Joao Goncalves‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
400 0 ‎‡a Joao Goncalves‏ ‎‡c investigador‏ ‎‡9 es‏
400 0 ‎‡a Joao Goncalves‏ ‎‡c investigador‏ ‎‡9 ast‏
670 ‎‡a Author's A novel Alu-mediated microdeletion at 11p13 removes WT1 in a patient with cryptorchidism and azoospermia‏
670 ‎‡a Author's A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor.‏
670 ‎‡a Author's Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins‏
670 ‎‡a Author's Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically‏
670 ‎‡a Author's Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience‏
670 ‎‡a Author's Anti-type II collagen antibodies detection and avidity in patients with oligoarticular and polyarticular forms of juvenile idiopathic arthritis.‏
670 ‎‡a Author's Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies.‏
670 ‎‡a Author's Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition‏
670 ‎‡a Author's Assessing combinatorial strategies to multimerize libraries of single-domain antibodies‏
670 ‎‡a Author's Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor.‏
670 ‎‡a Author's Biodistribution of a‏
670 ‎‡a Author's Biodistribution of a (67)Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag).‏
670 ‎‡a Author's Biosimilar DMARDs: What Does the Future Hold?‏
670 ‎‡a Author's Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity‏
670 ‎‡a Author's Biosimilars in rheumatology‏
670 ‎‡a Author's Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity‏
670 ‎‡a Author's Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies‏
670 ‎‡a Author's Characterization of plasma labile heme in hemolytic conditions‏
670 ‎‡a Author's Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.‏
670 ‎‡a Author's CIB1 and CIB2 are HIV-1 helper factors involved in viral entry.‏
670 ‎‡a Author's Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors‏
670 ‎‡a Author's Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors’ reply‏
670 ‎‡a Author's Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center‏
670 ‎‡a Author's Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies‏
670 ‎‡a Author's Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.‏
670 ‎‡a Author's Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication‏
670 ‎‡a Author's HIV-1 Vif and APOBEC3G: multiple roads to one goal‏
670 ‎‡a Author's HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation‏
670 ‎‡a Author's HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay‏
670 ‎‡a Author's HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.‏
670 ‎‡a Author's Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches‏
670 ‎‡a Author's Human mtDNA haplogroups and reduced male fertility: real association or hidden population substructuring‏
670 ‎‡a Author's Identification of SOX3 as an XX male sex reversal gene in mice and humans‏
670 ‎‡a Author's Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents‏
670 ‎‡a Author's Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.‏
670 ‎‡a Author's Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody‏
670 ‎‡a Author's Insights on the Formulation of Recombinant Proteins‏
670 ‎‡a Author's Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims‏
670 ‎‡a Author's Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.‏
670 ‎‡a Author's Is prnt a pseudogene? Identification of ram Prt in testis and ejaculated spermatozoa.‏
670 ‎‡a Author's M13 bacteriophage purification using poly‏
670 ‎‡a Author's M13 bacteriophage purification using poly(ionic liquids) as alternative separation matrices.‏
670 ‎‡a Author's miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication.‏
670 ‎‡a Author's Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds‏
670 ‎‡a Author's Modular Assembly of Reversible Multivalent Cancer-Cell-Targeting Drug Conjugates‏
670 ‎‡a Author's Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.‏
670 ‎‡a Author's Molecular construction of bionanoparticles: chimaeric SIV p17-HIV I p6 nanoparticles with minimal viral protein content.‏
670 ‎‡a Author's Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.‏
670 ‎‡a Author's Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population‏
670 ‎‡a Author's Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells‏
670 ‎‡a Author's Novel promoter and splice junction defects add to the genetic, clinical or geographic heterogeneity of beta-thalassaemia in the Portuguese population.‏
670 ‎‡a Author's Novel promoter and splice junction defects add to the genetic, clinical or geographic heterogeneity of?-thalassaemia in the Portuguese population‏
670 ‎‡a Author's Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands‏
670 ‎‡a Author's Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?‏
670 ‎‡a Author's Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation‏
670 ‎‡a Author's Phosphorylation of Vif and its role in HIV-1 replication‏
670 ‎‡a Author's Piezoelectric biosensors for biorecognition analysis: Application to the kinetic study of HIV-1 Vif protein binding to recombinant antibodies‏
670 ‎‡a Author's Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.‏
670 ‎‡a Author's Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance‏
670 ‎‡a Author's Rare double sex and mab-3-related transcription factor 1 regulatory variants in severe spermatogenic failure‏
670 ‎‡a Author's Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.‏
670 ‎‡a Author's Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs‏
670 ‎‡a Author's Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication‏
670 ‎‡a Author's Recombinant single-chain variable fragment and single domain antibody piezoimmunosensors for detection of HIV1 virion infectivity factor.‏
670 ‎‡a Author's SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis‏
670 ‎‡a Author's Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening‏
670 ‎‡a Author's The hepcidin gene promoter nc.-1010C > T; -582A > G haplotype modulates serum ferritin in individuals carrying the common H63D mutation in HFE gene.‏
670 ‎‡a Author's The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.‏
670 ‎‡a Author's The mutational spectrum of WT1 in male infertility.‏
670 ‎‡a Author's Therapeutic Antibody Engineering and Selection Strategies‏
670 ‎‡a Author's Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?‏
670 ‎‡a Author's Ultrastructure of HIV-1 genomic RNA‏
909 ‎‡a (scopus) 7103326175‏ ‎‡9 1‏
909 ‎‡a (scopus) 57200289025‏ ‎‡9 1‏
909 ‎‡a (scopus) 57200002849‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000212453715‏ ‎‡9 1‏
919 ‎‡a hiv1vifinteractionwithapobec3deaminasesanditscharacterizationbyanewsensitiveassay‏ ‎‡A HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay‏ ‎‡9 1‏
919 ‎‡a hiv1vifcandirectlyinhibitapolipoproteinbmrnaeditingenzymecatalyticpolypeptidelike3gmediatedcytidinedeaminationbyusingasingleaminoacidinteractionandwithoutproteindegradation‏ ‎‡A HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation‏ ‎‡9 1‏
919 ‎‡a hiv1vifandapobec3gmultipleroadsto1goal‏ ‎‡A HIV-1 Vif and APOBEC3G: multiple roads to one goal‏ ‎‡9 1‏
919 ‎‡a functionalneutralizationofhiv1vifproteinbyintracellularimmunizationinhibitsreversetranscriptionandviralreplication‏ ‎‡A Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication‏ ‎‡9 1‏
919 ‎‡a functionalanalysisofvifproteinshowslessrestrictionofhumanimmunodeficiencyvirustype2byapobec3g‏ ‎‡A Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.‏ ‎‡9 1‏
919 ‎‡a establishmentofabioluminescentcaninebcelllymphomaxenograftmodelformonitoringtumorprogressionandtreatmentresponseinpreclinicalstudies‏ ‎‡A Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies‏ ‎‡9 1‏
919 ‎‡a efficacyimmunogenicityandcostanalysisofasystematicswitchfromoriginatorinfliximabtobiosimilarctp13ofallpatientswithinflammatoryarthritisfromasinglecenter‏ ‎‡A Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center‏ ‎‡9 1‏
919 ‎‡a editorialantigenicresponsetoctp13andinfliximaboriginatorinibdshowssimilarepitoperecognitionevidencefrombasicsciencesupportssafeswitchingtobiosimilarsauthorsreply‏ ‎‡A Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors’ reply‏ ‎‡9 1‏
919 ‎‡a developmentofsyntheticlightchainantibodiesasnovelandpotenthivfusioninhibitors‏ ‎‡A Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors‏ ‎‡9 1‏
919 ‎‡a cib1andcib2arehiv1helperfactorsinvolvedinviralentry‏ ‎‡A CIB1 and CIB2 are HIV-1 helper factors involved in viral entry.‏ ‎‡9 1‏
919 ‎‡a chimericsmallantibodyfragmentsasstrategytodelivertherapeuticpayloads‏ ‎‡A Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.‏ ‎‡9 1‏
919 ‎‡a characterizationofplasmalabilehemeinhemolyticconditions‏ ‎‡A Characterization of plasma labile heme in hemolytic conditions‏ ‎‡9 1‏
919 ‎‡a celltypespecifictargetingwithsindbispseudotypedlentiviralvectorsdisplayinganticcr5singlechainantibodies‏ ‎‡A Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies‏ ‎‡9 1‏
919 ‎‡a camelizedrabbitderivedvhsingledomainintrabodiesagainstvifstronglyneutralizehiv1infectivity‏ ‎‡A Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity‏ ‎‡9 1‏
919 ‎‡a biosimilarsinrheumatology‏ ‎‡A Biosimilars in rheumatology‏ ‎‡9 1‏
919 ‎‡a biosimilarsanopportunitytoupdatetheproductinformationofbiologicaldrugsregardingtheirimmunogenicity‏ ‎‡A Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity‏ ‎‡9 1‏
919 ‎‡a biosimilardmardswhatdoesthefuturehold‏ ‎‡A Biosimilar DMARDs: What Does the Future Hold?‏ ‎‡9 1‏
919 ‎‡a biodistributionofa67galabeledantitnfvhhsingledomainantibodycontainingabacterialalbuminbindingdomainzag‏ ‎‡A Biodistribution of a (67)Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag).‏ ‎‡9 1‏
919 ‎‡a biodistributionofa‏ ‎‡A Biodistribution of a‏ ‎‡9 1‏
919 ‎‡a attenuationofhiv1replicationinprimaryhumancellswithadesignedzincfingertranscriptionfactor‏ ‎‡A Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor.‏ ‎‡9 1‏
919 ‎‡a assessingcombinatorialstrategiestomultimerizelibrariesofsingledomainantibodies‏ ‎‡A Assessing combinatorial strategies to multimerize libraries of single-domain antibodies‏ ‎‡9 1‏
919 ‎‡a antigenicresponsetoctp13andinfliximaboriginatorininflammatoryboweldiseasepatientsshowssimilarepitoperecognition‏ ‎‡A Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition‏ ‎‡9 1‏
919 ‎‡a anticanceractivityandantibodydependentcellmediatedcytotoxicityofnovelantinucleolinantibodies‏ ‎‡A Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies.‏ ‎‡9 1‏
919 ‎‡a antitype2collagenantibodiesdetectionandavidityinpatientswitholigoarticularandpolyarticularformsofjuvenileidiopathicarthritis‏ ‎‡A Anti-type II collagen antibodies detection and avidity in patients with oligoarticular and polyarticular forms of juvenile idiopathic arthritis.‏ ‎‡9 1‏
919 ‎‡a antitnfbiosimilarsinpsoriasisfromscientificevidencetorealworldexperience‏ ‎‡A Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience‏ ‎‡9 1‏
919 ‎‡a analysisofimmunogenicitydataintheproductinformationofbiologicaldrugsaneedtoreportimmunogenicitydatasystematically‏ ‎‡A Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically‏ ‎‡9 1‏
919 ‎‡a albuminbindingdomainfromstreptococcuszooepidemicusproteinzagasanovelstrategytoimprovethehalflifeoftherapeuticproteins‏ ‎‡A Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins‏ ‎‡9 1‏
919 ‎‡a novelreactiveepitopebasedantigentargetedbyserumautoantibodiesinoligoarticularandpolyarticularjuvenileidiopathicarthritisanddevelopmentofanelectrochemicalbiosensor‏ ‎‡A A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor.‏ ‎‡9 1‏
919 ‎‡a novelalumediatedmicrodeletionat11p13removeswt1inapatientwithcryptorchidismandazoospermia‏ ‎‡A A novel Alu-mediated microdeletion at 11p13 removes WT1 in a patient with cryptorchidism and azoospermia‏ ‎‡9 1‏
919 ‎‡a therapeuticantibodyengineeringandselectionstrategies‏ ‎‡A Therapeutic Antibody Engineering and Selection Strategies‏ ‎‡9 1‏
919 ‎‡a towardsinhibitionofvifapobec3ginteractionwhichproteintotarget‏ ‎‡A Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?‏ ‎‡9 1‏
919 ‎‡a ultrastructureofhiv1genomicrna‏ ‎‡A Ultrastructure of HIV-1 genomic RNA‏ ‎‡9 1‏
919 ‎‡a mutationalspectrumofwt1inmaleinfertility‏ ‎‡A The mutational spectrum of WT1 in male infertility.‏ ‎‡9 1‏
919 ‎‡a histonedeacetylaseinhibitorpanobinostatisapotentantitumoragentincaninediffuselargebcelllymphoma‏ ‎‡A The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.‏ ‎‡9 1‏
919 ‎‡a hepcidingenepromoternc1010ct582aghaplotypemodulatesserumferritininindividualscarryingthecommonh63dmutationinhfegene‏ ‎‡A The hepcidin gene promoter nc.-1010C > T; -582A > G haplotype modulates serum ferritin in individuals carrying the common H63D mutation in HFE gene.‏ ‎‡9 1‏
919 ‎‡a syntheticantibodydiscoveryagainstnativeantigensbycrisprcas9librarygenerationandendoplasmicreticulumscreening‏ ‎‡A Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening‏ ‎‡9 1‏
919 ‎‡a sb5showscrossimmunogenicitytoadalimumabbutnotinfliximabresultsinpatientswithinflammatoryboweldiseaseorrheumatoidarthritis‏ ‎‡A SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis‏ ‎‡9 1‏
919 ‎‡a recombinantsinglechainvariablefragmentandsingledomainantibodypiezoimmunosensorsfordetectionofhiv1virioninfectivityfactor‏ ‎‡A Recombinant single-chain variable fragment and single domain antibody piezoimmunosensors for detection of HIV1 virion infectivity factor.‏ ‎‡9 1‏
919 ‎‡a recombinantrabbitsinglechainantibodiesbindtothecatalyticand100terminaldomainsofhiv1integraseproteinandstronglyinhibithiv1replication‏ ‎‡A Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication‏ ‎‡9 1‏
919 ‎‡a recombinantantibodiesastherapeuticagentspathwaysformodelingnewbiodrugs‏ ‎‡A Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs‏ ‎‡9 1‏
919 ‎‡a reactivationoflatenthiv1expressionbyengineeredtaletranscriptionfactors‏ ‎‡A Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.‏ ‎‡9 1‏
919 ‎‡a raredoublesexandmab3relatedtranscriptionfactor1regulatoryvariantsinseverespermatogenicfailure‏ ‎‡A Rare double sex and mab-3-related transcription factor 1 regulatory variants in severe spermatogenic failure‏ ‎‡9 1‏
919 ‎‡a quantitativeanalysisofmolecularpartitiontowardslipidmembranesusingsurfaceplasmonresonance‏ ‎‡A Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance‏ ‎‡9 1‏
919 ‎‡a positionpaperfromtheportugueseassociationofhospit Alpha rmacistsforbiosimilartherapeuticantibodies‏ ‎‡A Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.‏ ‎‡9 1‏
919 ‎‡a piezoelectricbiosensorsforbiorecognitionanalysisapplicationtothekineticstudyofhiv1vifproteinbindingtorecombinantantibodies‏ ‎‡A Piezoelectric biosensors for biorecognition analysis: Application to the kinetic study of HIV-1 Vif protein binding to recombinant antibodies‏ ‎‡9 1‏
919 ‎‡a phosphorylationofvifanditsroleinhiv1replication‏ ‎‡A Phosphorylation of Vif and its role in HIV-1 replication‏ ‎‡9 1‏
919 ‎‡a phosphorylationofanovelsocsboxregulatesassemblyofthehiv1vifcul5complexthatpromotesapobec3gdegradation‏ ‎‡A Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation‏ ‎‡9 1‏
919 ‎‡a pharmacoeconomicsofbiosimilarswhatistheretogainfromthem‏ ‎‡A Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?‏ ‎‡9 1‏
919 ‎‡a nucleolinbasedtargetingstrategiesforcancertherapyfromtargeteddrugdeliverytocytotoxicligands‏ ‎‡A Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands‏ ‎‡9 1‏
919 ‎‡a novelpromoterandsplicejunctiondefectsaddtothegeneticclinicalorgeographicheterogeneityofthalassaemiaintheportuguesepopulation‏ ‎‡A Novel promoter and splice junction defects add to the genetic, clinical or geographic heterogeneity of?-thalassaemia in the Portuguese population‏ ‎‡9 1‏
919 ‎‡a novelpromoterandsplicejunctiondefectsaddtothegeneticclinicalorgeographicheterogeneityofbetathalassaemiaintheportuguesepopulation‏ ‎‡A Novel promoter and splice junction defects add to the genetic, clinical or geographic heterogeneity of beta-thalassaemia in the Portuguese population.‏ ‎‡9 1‏
919 ‎‡a novelhiv1knockdowntargetsidentifiedbyanenrichedkinasesphosphatasesshrnalibraryusingalongtermiterativescreeninjurkattcells‏ ‎‡A Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells‏ ‎‡9 1‏
919 ‎‡a nextgenerationsequencingofhereditaryhemochromatosisrelatedgenesnovellikelypathogenicvariantsfoundintheportuguesepopulation‏ ‎‡A Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population‏ ‎‡9 1‏
919 ‎‡a mutationsselectedinhiv2infectedpatientsfailingaregimenincludingatazanavir‏ ‎‡A Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.‏ ‎‡9 1‏
919 ‎‡a molecularconstructionofbionanoparticleschimaericsivp17hiv1p6nanoparticleswithminimalviralproteincontent‏ ‎‡A Molecular construction of bionanoparticles: chimaeric SIV p17-HIV I p6 nanoparticles with minimal viral protein content.‏ ‎‡9 1‏
919 ‎‡a modulationoftranslationfactorsgeneexpressionbyhistonedeacetylaseinhibitorsinbreastcancercells‏ ‎‡A Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.‏ ‎‡9 1‏
919 ‎‡a modularassemblyofreversiblemultivalentcancercelltargetingdrugconjugates‏ ‎‡A Modular Assembly of Reversible Multivalent Cancer-Cell-Targeting Drug Conjugates‏ ‎‡9 1‏
919 ‎‡a mitochondrialthioredoxinreductaseinhibitionseleniumstatusandnrf2activationaredeterminantfactorsmodulatingthetoxicityofmercurycompounds‏ ‎‡A Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds‏ ‎‡9 1‏
919 ‎‡a mirnaprofilingofhumannaivecd4tcellslinksmir34c5ptocellactivationandhivreplication‏ ‎‡A miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication.‏ ‎‡9 1‏
919 ‎‡a m13bacteriophagepurificationusingpolyionicliquidsasalternativeseparationmatrices‏ ‎‡A M13 bacteriophage purification using poly(ionic liquids) as alternative separation matrices.‏ ‎‡9 1‏
919 ‎‡a m13bacteriophagepurificationusingpoly‏ ‎‡A M13 bacteriophage purification using poly‏ ‎‡9 1‏
919 ‎‡a isprntapseudogeneidentificationoframprtintestisandejaculatedspermatozoa‏ ‎‡A Is prnt a pseudogene? Identification of ram Prt in testis and ejaculated spermatozoa.‏ ‎‡9 1‏
919 ‎‡a intrabodiestargetingthekaposisarcomaassociatedherpesviruslatencyantigeninhibitviralpersistenceinlymphomacells‏ ‎‡A Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.‏ ‎‡9 1‏
919 ‎‡a interactionsbetweentherapeuticproteinsandsmallmoleculesthesharedroleofperpetratorsandvictims‏ ‎‡A Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims‏ ‎‡9 1‏
919 ‎‡a insightsontheformulationofrecombinantproteins‏ ‎‡A Insights on the Formulation of Recombinant Proteins‏ ‎‡9 1‏
919 ‎‡a inhibitionofhivreplicationthroughsirnacarriedbycxcr4targetedchimericnanobody‏ ‎‡A Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody‏ ‎‡9 1‏
919 ‎‡a improvedserologicaldetectionofrheumatoidarthritisahighlyantigenicmimotopeofcarbonicanhydrase3selectedinamurinemodelbyphagedisplay‏ ‎‡A Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.‏ ‎‡9 1‏
919 ‎‡a immunogenicityofbiosimilarsforrheumaticdiseasesplaquepsoriasisandinflammatoryboweldiseaseareviewfromclinicaltrialsandregulatorydocuments‏ ‎‡A Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents‏ ‎‡9 1‏
919 ‎‡a identificationofsox3asan20malesexreversalgeneinmiceandhumans‏ ‎‡A Identification of SOX3 as an XX male sex reversal gene in mice and humans‏ ‎‡9 1‏
919 ‎‡a humanmtdnahaplogroupsandreducedmalefertilityrealassociationorhiddenpopulationsubstructuring‏ ‎‡A Human mtDNA haplogroups and reduced male fertility: real association or hidden population substructuring‏ ‎‡9 1‏
919 ‎‡a hostfactorsandhiv1replicationclinicalevidenceandpotentialtherapeuticapproaches‏ ‎‡A Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches‏ ‎‡9 1‏
919 ‎‡a hiv1vifproteinblocksthecytidinedeaminaseactivityofbcellspecificaidinecolibyasimilarmechanismofaction‏ ‎‡A HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000068699568‏
996 ‎‡2 ISNI|0000000070034792‏
996 ‎‡2 BLBNB|000288686‏
996 ‎‡2 PTBNP|1044691‏
996 ‎‡2 DNB|1029078742‏
996 ‎‡2 PTBNP|946060‏
996 ‎‡2 PTBNP|221853‏
996 ‎‡2 BLBNB|000526107‏
996 ‎‡2 DNB|1211027872‏
996 ‎‡2 PTBNP|238982‏
996 ‎‡2 ISNI|0000000070025896‏
996 ‎‡2 PTBNP|84819‏
996 ‎‡2 PTBNP|1451882‏
996 ‎‡2 PTBNP|1203421‏
996 ‎‡2 PTBNP|217544‏
996 ‎‡2 DNB|128712414‏
996 ‎‡2 LC|n 88207987‏
996 ‎‡2 PTBNP|1662764‏
996 ‎‡2 PTBNP|977378‏
996 ‎‡2 LC|no2021052499‏
996 ‎‡2 ISNI|000000011143227X‏
996 ‎‡2 BLBNB|001016962‏
996 ‎‡2 BNF|16630936‏
996 ‎‡2 ISNI|0000000499799093‏
996 ‎‡2 PTBNP|1365177‏
996 ‎‡2 ISNI|000000006858391X‏
996 ‎‡2 PTBNP|125319‏
996 ‎‡2 ISNI|0000000038731168‏
996 ‎‡2 BNF|17975308‏
996 ‎‡2 PTBNP|1054350‏
996 ‎‡2 ISNI|0000000070221221‏
996 ‎‡2 NTA|371621747‏
996 ‎‡2 BNF|12512686‏
996 ‎‡2 PTBNP|972808‏
996 ‎‡2 BLBNB|001456866‏
996 ‎‡2 ISNI|0000000070910369‏
996 ‎‡2 PTBNP|1624097‏
996 ‎‡2 LC|n 2024250015‏
996 ‎‡2 PTBNP|249826‏
996 ‎‡2 PTBNP|1797096‏
996 ‎‡2 ISNI|0000000070599427‏
996 ‎‡2 LC|no2018146090‏
996 ‎‡2 PTBNP|284991‏
996 ‎‡2 ISNI|0000000070988043‏
996 ‎‡2 BLBNB|000309159‏
996 ‎‡2 PTBNP|1537034‏
996 ‎‡2 PTBNP|1439264‏
996 ‎‡2 BLBNB|000523903‏
996 ‎‡2 PTBNP|1237761‏
996 ‎‡2 PTBNP|1342676‏
996 ‎‡2 BLBNB|001123634‏
996 ‎‡2 ISNI|0000000069095395‏
996 ‎‡2 PTBNP|1571062‏
996 ‎‡2 PTBNP|1374974‏
996 ‎‡2 ISNI|0000000068601620‏
996 ‎‡2 PTBNP|1237647‏
996 ‎‡2 PLWABN|9810572156105606‏
996 ‎‡2 ISNI|0000000069311983‏
996 ‎‡2 ISNI|0000000070935144‏
996 ‎‡2 BLBNB|000264327‏
996 ‎‡2 ISNI|0000000068612418‏
996 ‎‡2 ISNI|0000000443581132‏
996 ‎‡2 BNF|16659266‏
996 ‎‡2 PTBNP|959628‏
996 ‎‡2 LC|n 96097851‏
996 ‎‡2 PTBNP|1105476‏
996 ‎‡2 ISNI|0000000073465846‏
996 ‎‡2 PTBNP|1640526‏
996 ‎‡2 PTBNP|1198428‏
996 ‎‡2 ISNI|0000000030001144‏
996 ‎‡2 BLBNB|000458895‏
996 ‎‡2 PTBNP|37578‏
996 ‎‡2 ISNI|000000006769508X‏
996 ‎‡2 ISNI|0000000026643806‏
996 ‎‡2 PTBNP|1013494‏
996 ‎‡2 PTBNP|1001132‏
996 ‎‡2 SUDOC|166712558‏
996 ‎‡2 ISNI|0000000140948654‏
996 ‎‡2 ISNI|0000000070529613‏
996 ‎‡2 PTBNP|190680‏
996 ‎‡2 LC|no2024107056‏
996 ‎‡2 PTBNP|1906150‏
996 ‎‡2 PTBNP|1452367‏
996 ‎‡2 DNB|1157222692‏
996 ‎‡2 PTBNP|1690785‏
996 ‎‡2 BLBNB|000446689‏
996 ‎‡2 ISNI|0000000428148031‏
996 ‎‡2 PTBNP|1774154‏
996 ‎‡2 ISNI|0000000070293970‏
996 ‎‡2 LC|n 94003183‏
996 ‎‡2 BLBNB|000342792‏
996 ‎‡2 PLWABN|9811344604105606‏
996 ‎‡2 ISNI|000000002664717X‏
996 ‎‡2 DNB|1056700777‏
996 ‎‡2 LC|no2018000201‏
996 ‎‡2 BLBNB|000496912‏
996 ‎‡2 LC|n 2010201870‏
996 ‎‡2 PTBNP|1689187‏
996 ‎‡2 ISNI|0000000428288640‏
996 ‎‡2 ISNI|0000000068089620‏
996 ‎‡2 ISNI|0000000072826806‏
996 ‎‡2 PTBNP|267348‏
996 ‎‡2 BLBNB|000256243‏
996 ‎‡2 ISNI|0000000069592770‏
996 ‎‡2 ISNI|0000000428124582‏
996 ‎‡2 ISNI|0000000070394018‏
996 ‎‡2 LC|n 96099112‏
996 ‎‡2 LC|n 2009079961‏
996 ‎‡2 BLBNB|001417958‏
996 ‎‡2 LC|no2014150095‏
996 ‎‡2 ISNI|0000000070633867‏
996 ‎‡2 LC|n 2008217212‏
996 ‎‡2 PTBNP|80836‏
996 ‎‡2 LC|n 2014005685‏
996 ‎‡2 SUDOC|276292057‏
996 ‎‡2 BLBNB|001125229‏
996 ‎‡2 ISNI|0000000068679874‏
996 ‎‡2 LC|n 2008216363‏
996 ‎‡2 PTBNP|1823021‏
996 ‎‡2 SUDOC|253500664‏
996 ‎‡2 BLBNB|001017427‏
996 ‎‡2 ISNI|0000000069909045‏
996 ‎‡2 PTBNP|1208983‏
996 ‎‡2 BLBNB|001179575‏
996 ‎‡2 PTBNP|167887‏
996 ‎‡2 PTBNP|1569206‏
996 ‎‡2 PTBNP|1148577‏
996 ‎‡2 PTBNP|37534‏
996 ‎‡2 PTBNP|1632854‏
996 ‎‡2 ISNI|0000000069718521‏
996 ‎‡2 PTBNP|1884421‏
996 ‎‡2 DNB|1324222743‏
996 ‎‡2 LC|no2010052273‏
996 ‎‡2 NTA|373491972‏
996 ‎‡2 BLBNB|000208224‏
996 ‎‡2 PTBNP|1737617‏
996 ‎‡2 PTBNP|1442248‏
996 ‎‡2 ISNI|000000007094370X‏
996 ‎‡2 PTBNP|1315316‏
996 ‎‡2 ISNI|0000000069718230‏
996 ‎‡2 PTBNP|1533230‏
996 ‎‡2 LC|n 85290946‏
996 ‎‡2 SUDOC|112352022‏
996 ‎‡2 PTBNP|285503‏
996 ‎‡2 SUDOC|273508946‏
996 ‎‡2 PTBNP|285291‏
996 ‎‡2 ISNI|0000000070026880‏
996 ‎‡2 PTBNP|123733‏
996 ‎‡2 DNB|1320816606‏
996 ‎‡2 PTBNP|199272‏
996 ‎‡2 ISNI|000000006708895X‏
996 ‎‡2 DNB|1124076441‏
996 ‎‡2 DNB|105629907X‏
996 ‎‡2 PTBNP|1489227‏
996 ‎‡2 ISNI|0000000050497052‏
996 ‎‡2 NUKAT|n 2017085474‏
996 ‎‡2 LC|no2022059619‏
996 ‎‡2 ISNI|0000000067524109‏
996 ‎‡2 ISNI|0000000068617622‏
996 ‎‡2 PTBNP|37587‏
996 ‎‡2 PTBNP|37586‏
996 ‎‡2 PTBNP|1718645‏
996 ‎‡2 LC|no2018159524‏
996 ‎‡2 ISNI|0000000077391637‏
996 ‎‡2 SUDOC|158637348‏
996 ‎‡2 ISNI|0000000068688199‏
996 ‎‡2 BLBNB|000322313‏
996 ‎‡2 BLBNB|000219830‏
996 ‎‡2 DNB|1138950823‏
996 ‎‡2 PTBNP|1049126‏
996 ‎‡2 PTBNP|1357116‏
996 ‎‡2 ISNI|0000000067669594‏
996 ‎‡2 ISNI|0000000428285642‏
996 ‎‡2 PTBNP|1431437‏
996 ‎‡2 LC|n 00097695‏
996 ‎‡2 ISNI|0000000067622155‏
996 ‎‡2 ISNI|0000000512337839‏
996 ‎‡2 PTBNP|1195506‏
996 ‎‡2 DNB|1122061587‏
996 ‎‡2 PTBNP|287803‏
996 ‎‡2 ISNI|0000000069122605‏
996 ‎‡2 LC|n 2023253151‏
996 ‎‡2 PTBNP|257544‏
996 ‎‡2 PTBNP|963391‏
996 ‎‡2 DNB|121394514‏
996 ‎‡2 LC|n 94030820‏
996 ‎‡2 PTBNP|1383403‏
996 ‎‡2 ISNI|0000000048375857‏
996 ‎‡2 PTBNP|1386575‏
996 ‎‡2 LC|no2001019124‏
996 ‎‡2 BLBNB|001010398‏
996 ‎‡2 ISNI|0000000070943953‏
996 ‎‡2 LC|n 2007206487‏
996 ‎‡2 ISNI|0000000028540624‏
996 ‎‡2 LC|no2010051162‏
996 ‎‡2 BLBNB|000385666‏
996 ‎‡2 PTBNP|1657374‏
996 ‎‡2 LC|n 2020184073‏
996 ‎‡2 PTBNP|144771‏
996 ‎‡2 ISNI|0000000069299910‏
996 ‎‡2 BLBNB|000219825‏
996 ‎‡2 BLBNB|000219826‏
996 ‎‡2 DNB|1259287815‏
996 ‎‡2 PTBNP|37585‏
996 ‎‡2 PTBNP|1900512‏
996 ‎‡2 SUDOC|153094354‏
996 ‎‡2 PTBNP|1472514‏
996 ‎‡2 LC|no2001047912‏
996 ‎‡2 LC|no2024019863‏
996 ‎‡2 ISNI|0000000070998479‏
996 ‎‡2 SUDOC|142736619‏
996 ‎‡2 PTBNP|1920596‏
996 ‎‡2 PTBNP|1483444‏
996 ‎‡2 BLBNB|000219828‏
996 ‎‡2 ISNI|0000000068611562‏
996 ‎‡2 BIBSYS|90806258‏
996 ‎‡2 BLBNB|000292932‏
996 ‎‡2 PTBNP|1917777‏
996 ‎‡2 SUDOC|197931146‏
996 ‎‡2 ISNI|0000000070607108‏
996 ‎‡2 PTBNP|1774114‏
996 ‎‡2 ISNI|0000000080396535‏
996 ‎‡2 ISNI|0000000070406701‏
996 ‎‡2 PTBNP|1762030‏
996 ‎‡2 J9U|987007456024205171‏
996 ‎‡2 ISNI|0000000041491687‏
996 ‎‡2 BLBNB|000228543‏
996 ‎‡2 LC|n 82016155‏
996 ‎‡2 ISNI|0000000069991413‏
996 ‎‡2 ISNI|0000000080527742‏
996 ‎‡2 PTBNP|1563436‏
996 ‎‡2 PTBNP|1410287‏
996 ‎‡2 BLBNB|001556297‏
996 ‎‡2 PTBNP|1789177‏
996 ‎‡2 ISNI|0000000070623861‏
996 ‎‡2 BLBNB|000625046‏
996 ‎‡2 LC|no2011178317‏
996 ‎‡2 SUDOC|26721037X‏
996 ‎‡2 ISNI|0000000070194024‏
996 ‎‡2 BNC|981058612203106706‏
996 ‎‡2 DNB|1180509501‏
996 ‎‡2 ISNI|0000000430285203‏
996 ‎‡2 PTBNP|1664433‏
996 ‎‡2 ISNI|0000000077934494‏
996 ‎‡2 ISNI|0000000070817914‏
996 ‎‡2 PTBNP|41922‏
996 ‎‡2 LC|n 82056832‏
996 ‎‡2 ISNI|000000007093562X‏
996 ‎‡2 LC|n 2015245590‏
996 ‎‡2 LC|nb2014021781‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏